Answers are grounded in this paper and cite their sources.
Short-term fasting and fasting-mimicking diets (FMDs) have been proposed to widen the therapeutic window of cancer treatment by protecting normal tissues while sensitizing tumor cells, an approach termed differential stress resistance. Although preclinical studies support the effectiveness of this strategy, clinical studies have produced heterogeneous and frequently confounded results. For instance, favorable reports in patients with triple-negative breast cancer (TNBC) have stemmed from small, non-randomized studies that involved external or imbalanced comparators and carried a serious-to-critical risk of bias. The randomized DIRECT trial found no change in pathological complete response or toxicity in the intention-to-treat analysis. Furthermore, its secondary signals were confounded by baseline subtype imbalance and asymmetric dexamethasone use. Adherence during chemotherapy is poor, and the confirmatory phase III trial DIRECT-2 has been suspended because of a lack of demonstrable efficacy. Mechanistically, fasting may also promote tumor survival through autophagy and nutrient scavenging, while post-fast refeeding can expand mutant stem cells. This review appraises the mechanistic rationale and clinical evidence for implementing short-term fasting and FMDs in patients with cancer, with explicit attention to bias, and identifies key priorities for determining whether fasting-based strategies have the potential to become standard adjuncts or remain niche interventions.
No takes yet. Share an insight, caveat, or question.
Kadam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: